Diversified Trust Co. Increases Stock Holdings in IDEXX Laboratories, Inc. $IDXX

Diversified Trust Co. increased its position in shares of IDEXX Laboratories, Inc. (NASDAQ:IDXX) by 223.5% in the 4th quarter, according to the company in its most recent disclosure with the Securities and Exchange Commission. The fund owned 4,199 shares of the company’s stock after purchasing an additional 2,901 shares during the period. Diversified Trust Co.’s holdings in IDEXX Laboratories were worth $2,841,000 at the end of the most recent quarter.

A number of other institutional investors also recently bought and sold shares of IDXX. Virtus Advisers LLC purchased a new stake in shares of IDEXX Laboratories in the 3rd quarter valued at approximately $26,000. WealthCollab LLC purchased a new stake in shares of IDEXX Laboratories during the 2nd quarter valued at approximately $30,000. J.Safra Asset Management Corp purchased a new stake in shares of IDEXX Laboratories during the 3rd quarter valued at approximately $31,000. Armstrong Advisory Group Inc. lifted its holdings in IDEXX Laboratories by 55.9% in the third quarter. Armstrong Advisory Group Inc. now owns 53 shares of the company’s stock valued at $34,000 after acquiring an additional 19 shares during the last quarter. Finally, Salomon & Ludwin LLC acquired a new position in IDEXX Laboratories in the third quarter valued at approximately $35,000. 87.84% of the stock is owned by hedge funds and other institutional investors.

IDEXX Laboratories Stock Down 1.4%

Shares of IDXX opened at $570.21 on Wednesday. The company’s 50-day simple moving average is $639.93 and its 200-day simple moving average is $663.76. The company has a debt-to-equity ratio of 0.23, a quick ratio of 0.90 and a current ratio of 1.23. IDEXX Laboratories, Inc. has a 1 year low of $356.14 and a 1 year high of $769.98. The stock has a market capitalization of $45.34 billion, a PE ratio of 43.63, a P/E/G ratio of 3.51 and a beta of 1.66.

IDEXX Laboratories (NASDAQ:IDXX) last announced its quarterly earnings data on Monday, February 2nd. The company reported $2.92 earnings per share for the quarter, missing analysts’ consensus estimates of $2.93 by ($0.01). IDEXX Laboratories had a net margin of 24.62% and a return on equity of 69.78%. The business had revenue of $1.09 billion during the quarter, compared to analyst estimates of $1.07 billion. During the same quarter last year, the firm posted $2.53 EPS. The company’s revenue for the quarter was up 14.3% on a year-over-year basis. IDEXX Laboratories has set its FY 2026 guidance at 14.290-14.800 EPS. Analysts forecast that IDEXX Laboratories, Inc. will post 11.93 earnings per share for the current fiscal year.

Analysts Set New Price Targets

IDXX has been the subject of several recent analyst reports. Wall Street Zen cut IDEXX Laboratories from a “strong-buy” rating to a “buy” rating in a research note on Saturday, February 28th. Barclays decreased their price target on IDEXX Laboratories from $850.00 to $800.00 and set an “overweight” rating on the stock in a research note on Thursday, February 5th. UBS Group lowered their price target on IDEXX Laboratories from $750.00 to $730.00 and set a “neutral” rating for the company in a report on Tuesday, February 3rd. BTIG Research cut their price objective on IDEXX Laboratories from $830.00 to $800.00 and set a “buy” rating for the company in a research report on Tuesday, February 3rd. Finally, Weiss Ratings lowered shares of IDEXX Laboratories from a “buy (b-)” rating to a “hold (c+)” rating in a report on Thursday, January 29th. Seven equities research analysts have rated the stock with a Buy rating and three have assigned a Hold rating to the company’s stock. According to data from MarketBeat.com, the company has an average rating of “Moderate Buy” and an average target price of $783.33.

Insiders Place Their Bets

In other IDEXX Laboratories news, Director Sophie V. Vandebroek sold 1,464 shares of the business’s stock in a transaction on Tuesday, February 17th. The shares were sold at an average price of $628.62, for a total value of $920,299.68. Following the completion of the transaction, the director owned 648 shares in the company, valued at $407,345.76. The trade was a 69.32% decrease in their ownership of the stock. The transaction was disclosed in a legal filing with the SEC, which is available at the SEC website. Also, EVP Michael G. Erickson sold 5,371 shares of the company’s stock in a transaction on Tuesday, February 17th. The stock was sold at an average price of $627.38, for a total value of $3,369,657.98. Following the sale, the executive vice president directly owned 12,693 shares in the company, valued at $7,963,334.34. This represents a 29.73% decrease in their position. The SEC filing for this sale provides additional information. Over the last quarter, insiders have sold 45,957 shares of company stock valued at $29,862,109. Corporate insiders own 0.98% of the company’s stock.

About IDEXX Laboratories

IDEXX Laboratories, Inc (NASDAQ: IDXX) is a global developer, manufacturer and provider of diagnostic products and services primarily for the animal health, water testing and food safety markets. Headquartered in Westbrook, Maine, the company supplies in-clinic diagnostic instruments, consumables, reference laboratory testing and practice-management tools that support veterinarians, livestock and dairy producers, and utilities and food producers worldwide.

IDEXX’s product portfolio includes point-of-care tests and immunoassays designed for rapid diagnosis in veterinary clinics, in-clinic chemistry and hematology analyzers, automated urinalysis systems, and digital diagnostic solutions.